Using BALB/c mice bearing 4T1 triple-negative breast cancer flank tumors, we tested whether CpG+OX40 might activate an anti-tumor response and whether this response would be enhanced by combination with RT. The gene discussed is TNFRSF4; the disease is neoplasm.